Both the TYRX™ Neuro Absorbable Antibacterial Envelope and the TYRX™ Cardiac Absorbable Antibacterial Envelope for cardiac implantable electronic devices (CIEDs) are designed to help reduce infection, and they share many of the same features.
Clinical data for the TYRX Cardiac Envelope show a reduced rate of infections among high-risk patients who received a CIED.
Strong clinical data associates the use of the TYRX Antibacterial Envelope with a significantly lower rate of cardiac implantable electronic device (CIED) infections — infections that are both costly to the healthcare system and pose a significant mortality risk to patients.
The COMMAND, C&C (Citadel & Centurion), Valley, Vanderbilt (Non-Absorbable) and UPMC Studies were performed utilizing the TYRX™ Non-Absorbable Antibacterial Envelope.
The Vanderbilt (Absorbable) Study was performed utilizing the Absorbable TYRX™ Absorbable Antibacterial Envelope.
Bloom HL et al. Pacing Clin Electrophysiol. 2011;34(2):133-142.
Mittal S et al. Heart Rhythm. 2014;11(4):595-601
Shariff N et al. J Cardio Electrophysiol. 2015. Online publication.
Henrikson CA et al. JACC EP 2017; 3(10):1158-1167.
Sohail MR et al. Arch Intern Med. 2011;171(20):1821-1828.